This is in line with several studies that reported elevated levels of circulating inflammatory markers, including tumor necrosis factor and IL-6, in hypertrophic cardiomyopathy (HCM), supporting the anti-inflammatory role of these treatments in cardiac health [55,56]. Here, IL6 is linked to hypertrophic cardiomyopathy.